Growth Metrics

Halozyme Therapeutics (HALO) Amortization - Intangibles (2022 - 2025)

Historic Amortization - Intangibles for Halozyme Therapeutics (HALO) over the last 4 years, with Q4 2025 value amounting to $23.4 million.

  • Halozyme Therapeutics' Amortization - Intangibles rose 3160.68% to $23.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $76.7 million, marking a year-over-year increase of 790.02%. This contributed to the annual value of $76.7 million for FY2025, which is 790.02% up from last year.
  • Per Halozyme Therapeutics' latest filing, its Amortization - Intangibles stood at $23.4 million for Q4 2025, which was up 3160.68% from $17.8 million recorded in Q3 2025.
  • Over the past 5 years, Halozyme Therapeutics' Amortization - Intangibles peaked at $27.2 million during Q3 2022, and registered a low of $4.6 million during Q4 2022.
  • In the last 4 years, Halozyme Therapeutics' Amortization - Intangibles had a median value of $17.8 million in 2023 and averaged $17.6 million.
  • The largest annual percentage gain for Halozyme Therapeutics' Amortization - Intangibles in the last 5 years was 29020.21% (2023), contrasted with its biggest fall of 2519.77% (2023).
  • Halozyme Therapeutics' Amortization - Intangibles (Quarter) stood at $4.6 million in 2022, then surged by 290.2% to $17.8 million in 2023, then changed by 0.0% to $17.8 million in 2024, then skyrocketed by 31.61% to $23.4 million in 2025.
  • Its Amortization - Intangibles stands at $23.4 million for Q4 2025, versus $17.8 million for Q3 2025 and $17.8 million for Q2 2025.